Cambridge startup Codiak BioSciences Inc., which launched in November with $31 million in financing, Tuesday said that it has raised another $61 million in a second funding round.
The new investment, bringing Codiak’s total financing to $92 million, was led by Flagship Ventures of Cambridge and ARCH Venture Partners of Chicago, which also led the launch round. Other investors joining both financing rounds included Alaska Permanent Fund, Alexandria Venture Investments, and Fidelity Management and Research Co.
Codiak is working with tiny membrane sacs known as exosomes that carry information about red blood cells to diagnose and treat cancer and other diseases. Its chief executive, Doug Williams, was formerly the top research and development executive at Biogen Inc.
Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.